Recent evidence in mouse models of breast and colorectal cancer, suggest that BRCA2-deficient tumours are more susceptible to ICIs than BRCA1-deficient tumour (Samstein et al., 2020; Zhou and Li 2021). Here, BRCA2 is linked to neoplasm.